PROCEPT BioRobotics Corporation (PRCT)

Wie das Geld verdient wird

Classic razor-and-blade. PROCEPT sells or rents the robotic console to a hospital — a one-off capital sale — and then earns recurring revenue on every procedure, because each Aquablation treatment consumes a single-use disposable handpiece. A third, smaller stream comes from service contracts on the installed base. The economics shift with the mix: in fiscal 2025 handpieces and consumables were already the largest line, so the installed base, not the year's console sales, is what drives the revenue line. Hospitals are the paying customers, and they in turn bill Medicare and commercial insurers for the procedure — so adequate reimbursement, not the surgeon alone, decides whether a system gets used.

Umsatz nach Segment

Once a hospital installs an AquaBeam or HYDROS console, trains its urologists and builds a BPH pathway around it, the handpieces it buys are PROCEPT's and nobody else's — the console is a closed system, and a switch means writing off the capital equipment and retraining the surgeons. That is a real but narrow advantage: it holds the existing base, it does not win the next hospital. PROCEPT still has to displace entrenched alternatives — TURP, laser resection and Boston Scientific's Rezum, and Teleflex's UroLift — against competitors the company itself describes as larger and better resourced, and the whole franchise rests on one therapy in one indication.

The two halves of the business behave differently. Handpiece demand follows BPH procedure volume, which is driven by an ageing male population and by a condition that does not go away when the economy turns — that part is close to defensive. System placements are capital purchases: they compete for a hospital's equipment budget, and the company discloses that customers face cost-containment pressure, which is exactly where a weaker budget cycle shows up. The filing does not discuss seasonality or economic cycles directly, so this reading comes from the structure of the revenue, not from a company statement.

Wichtigste Risiken

• A history of losses, with no assurance of profitability — The company discloses significant net losses since inception and continuing operating losses, and states it may never achieve or sustain profitability; the 2025 net loss was $95.6 million.
• Everything depends on one product family — Its business is tied to commercial success of the robotic systems and their handpieces for Aquablation therapy; a setback in that single franchise has nowhere else to land.
• Surgeons and hospitals may not adopt the therapy — Growth requires market acceptance by hospitals, urologists and patients of a treatment that competes with long-established procedures; the company also flags limited experience in sales, marketing and building brand awareness.
• Reimbursement can change against them — Hospitals buy only if third-party payors cover the procedure adequately; the filing flags coverage volatility and possible changes to reimbursement rates for BPH treatments.
• Single-source suppliers — The company states it relies on third-party suppliers, almost all of them single source, for components, sub-assemblies and materials, which exposes it to shortages and price increases as it scales manufacturing.
• Competition from far larger companies — It competes with resective surgical treatments including TURP and laser therapies from Boston Scientific, and with Rezum and Teleflex's UroLift, against rivals with greater financial and commercial resources.
• Regulation and intellectual property — Ongoing regulatory compliance and post-market scrutiny of the devices, plus the cost and uncertainty of protecting patents and defending against intellectual-property litigation, are disclosed risks. Product liability exposure is flagged as well.

The annual report does not disclose any customer concentration figure, and no single customer is identified as accounting for 10% or more of revenue. Structurally, revenue is spread across the hospitals and surgical centres that have installed a system, but no number is available to confirm how concentrated that base is.